Key Updates
Eli Lilly declined 2.35% to $890.15 since the March 18th report, breaking below the $900 psychological support level and extending YTD losses to -17.17%. The downward pressure persists following HSBC's March 17th downgrade to Reduce with an $850 price target, which triggered a reassessment of the obesity drug market's total addressable market from $150 billion to $80-120 billion by 2032. While Lilly launched its Employer Connect platform on March 5th to expand Zepbound access and demonstrated AI-driven manufacturing improvements, these positive developments have been overshadowed by fundamental concerns about market saturation, pricing sustainability, and the viability of the cash-pay model amid potential economic headwinds.
Current Trend
LLY is in a pronounced downtrend, declining 17.17% YTD and 13.48% over the past month. The stock has broken through multiple support levels: $1,000 (psychological), $970, $935, $911, and now $900. The 6-month performance of +22.86% demonstrates the sharp reversal from the late 2024/early 2025 momentum that propelled Lilly to a $1 trillion market cap. The recent 5-day decline of -1.83% and 1-day decline of -0.76% indicate continued selling pressure without signs of stabilization. The $850 price target from HSBC represents an additional 4.5% downside from current levels, suggesting analysts see limited near-term catalysts for recovery.
Investment Thesis
The investment thesis centers on Lilly's dominant position in the GLP-1 obesity and diabetes market, with Mounjaro ($23 billion 2024 revenue) and Zepbound ($13.5 billion) accounting for over half of the company's $65 billion total revenue. The thesis assumes continued market expansion as obesity affects over 100 million American adults and costs the U.S. economy $1.7 trillion annually, with roughly half of commercially insured employees lacking coverage. Lilly's manufacturing scale-up using AI-powered digital twins addresses previous supply constraints, while the Employer Connect platform at $449 per dose aims to expand market penetration through direct-to-employer channels. The upcoming oral GLP-1 Orforglipron represents potential product line expansion beyond injectables.
Thesis Status
The investment thesis faces significant challenges as market expectations recalibrate. HSBC's downgrade directly questions the core assumption of a $150 billion obesity drug market by 2030, instead projecting $80-120 billion by 2032 with intensifying pricing competition. The cash-pay model's sustainability is under scrutiny, particularly given concerns about middle-class affordability amid potential AI-driven job disruption. While Lilly's 25% revenue growth forecast for 2026 contrasts favorably with Novo Nordisk's 5-13% decline projection, the comparison highlights competitive dynamics that may compress margins. The thesis remains intact regarding manufacturing capabilities and product efficacy (20.9% body weight loss for Zepbound 15mg dose), but market size and pricing assumptions require downward revision. The stock's valuation at current levels reflects "priced to perfection" concerns, making execution risk more consequential.
Key Drivers
The primary driver is market reassessment of GLP-1 total addressable market size and sustainability. HSBC's March 17th downgrade and concerns about cash-pay economics have catalyzed the selloff. Positively, the March 5th Employer Connect launch with fifteen program administrators including Mark Cuban Cost Plus Drug Company and GoodRx represents a strategic distribution expansion addressing the coverage gap for 50% of commercially insured employees. AI-driven manufacturing improvements resolved FDA shortage designations and enabled material production increases, though supply normalization may reduce scarcity-driven pricing power. Competitive dynamics with Novo Nordisk intensifying and questions about oral GLP-1 efficacy versus injectables add uncertainty to future market share assumptions.
Technical Analysis
LLY exhibits bearish momentum across all timeframes except the 6-month view. The stock broke below $900, a critical psychological support level, with the next technical support at HSBC's $850 price target. The 50-day and 200-day moving averages are likely in bearish crossover territory given the -13.48% monthly decline. Volume patterns during the March 17th decline (worst S&P 500 performer that day with -4%) suggest institutional distribution. Resistance levels are now established at $911 (previous support), $935, $970, and $1,000. The -17.17% YTD performance significantly underperforms the broader healthcare sector, which HSBC recommends as defensive. Without a fundamental catalyst or technical reversal pattern, the path of least resistance remains downward toward the $850 level. The 22.86% six-month gain provides context for the current correction as a reversion from overextended levels reached in late 2024.
Bull Case
- Manufacturing scale and AI optimization: Lilly successfully used digital twin technology to materially increase GLP-1 production, resolving FDA shortages and enabling revenue growth, with Mounjaro doubling to $23 billion and Zepbound surging to $13.5 billion in 2024. Source: Forbes
- Employer Connect platform expansion: The March 5th launch with fifteen administrators including Mark Cuban Cost Plus Drug Company addresses the coverage gap for 50% of commercially insured employees, offering Zepbound at $449 across all doses to expand market penetration beyond traditional insurance channels. Source: PR Newswire
- Market leadership position: Zepbound was the most prescribed weight management medication in 2025, with clinical data showing 20.9% body weight loss at 15mg dose, while Lilly forecasts 25% revenue growth in 2026 versus Novo Nordisk's 5-13% decline projection. Source: CNBC
- Massive addressable market: Obesity affects over 100 million American adults and costs the U.S. economy more than $1.7 trillion annually, with roughly half of commercially insured employees lacking coverage for obesity management medications, representing substantial untapped demand. Source: PR Newswire
- Historic market cap achievement: Manufacturing success and GLP-1 revenue growth helped propel Lilly to become the first healthcare company to reach a $1 trillion market capitalization in late 2024, demonstrating investor confidence in the franchise value. Source: Forbes
Bear Case
- Total addressable market significantly overestimated: HSBC downgraded to Reduce with $850 price target, projecting obesity drug market will reach only $80-120 billion by 2032 versus consensus $150 billion by 2030, with intensifying pricing competition expected to compress margins and limit market expansion. Source: CNBC
- Cash-pay model sustainability concerns: HSBC questions whether middle-class Americans can sustain $299-449 monthly out-of-pocket costs for Zepbound, particularly amid potential job losses from AI disruption, threatening the direct-to-consumer revenue model that bypasses insurance coverage limitations. Source: Morningstar
- Valuation priced to perfection: HSBC warns the stock is priced to perfection with limited upside, as evidenced by the -14% YTD decline following the downgrade, with analysts questioning sustainability of bullish outlook particularly regarding upcoming oral GLP-1 Orforglipron effectiveness versus injectables. Source: CNBC
- Competitive dynamics intensifying: Novo Nordisk's 55% decline over the past year serves as a warning sign, with HSBC expecting pricing pressures and market share competition to intensify as both companies fight for dominance in a potentially smaller-than-expected market. Source: Morningstar
- Revenue concentration risk: GLP-1 drugs (Mounjaro and Zepbound) account for more than half of Lilly's $65 billion total revenue, creating significant exposure to market dynamics, regulatory changes, and competitive threats in a single therapeutic category with uncertain long-term growth trajectory. Source: Forbes